Eribulin in Combination With Cyclophosphamide in Patients With Solid Tumor Malignancies

• Sponsor: University of California, San Francisco (Other)
• Overall Status: Completed
• CT.gov ID: NCT01554371
• Collaborator: Eisai Inc. (Industry)
• Enrollment: 44
• Location: 1
• Arms: 3
• Actual Duration (Months): 93.1
• Patients Per Site Per Month: 0.5

Study Details

Study Description

Brief Summary

The purpose of this study is to test the safety of eribulin (Halaven™) and cyclophosphamide (Cytoxan®) given together at different doses. This study will look at what effects, good and/or bad, that these drugs have on solid tumors. Eribulin is a drug that has been approved by the FDA for breast cancer that has spread to other parts of the body. Cyclophosphamide has been approved for different types of cancers (including breast cancer). However, the combination of eribulin and cyclophosphamide is considered experimental; that means this combination has not been approved by the FDA.

The funding for this study is provided by Eisai Inc., the maker of eribulin.

Condition or Disease	Intervention/Treatment	Phase
Malignant Solid Tumour; Breast Cancer Nos Metastatic Recurrent; Neuropathy	Drug: Eribulin; Drug: Cyclophosphamide	Phase 1/Phase 2

Detailed Description

This is a phase Ib/II trial designed to determine the maximum tolerated dose (MTD) and does limiting toxicities (DLTs) of the combination of eribulin and cyclophosphamide in solid tumors and make preliminary estimates regarding efficacy of this treatment in patients with advanced breast cancer.

The study includes a standard dose-confirmation schema (phase Ib portion) enrolling 3 to 6 patients/subjects, with any solid tumors, per cohort (3+3 design) with a total of 18 patients. The dose-expansion (phase II portion) will enroll 40 patients with advanced breast cancer to detect an effect size of 15% with a power of 80% with endpoints of safety, efficacy, and clinical benefit rate. A maximum of 58 patients will be enrolled on the phase Ib and II portions of this trial combined and will be treated until disease progression or toxicity mandate treatment change.

Eribulin is a non-taxane microtubule inhibitor that is FDA approved as monotherapy for the treatment of taxane and anthracycline resistant metastatic breast cancer. The combination of docetaxel and cyclophosphamide is a well-accepted adjuvant chemotherapy regimen that has become an increasingly common therapeutic choice for intermediate risk early stage breast cancer. Eribulin has a favorable toxicity profile compared to docetaxel with the most common adverse reactions (incidence ≤25%) including neutropenia, anemia, asthenia/fatigue, alopecia, peripheral neuropathy, nausea, and constipation. Eribulin appears to have activity in taxane resistant disease, making it an attractive partner with cyclophosphamide.

Neuropathy can be a devastating complication from adjuvant chemotherapy and in the metastatic setting, may limit effective therapy and reduce quality of life. Understanding the host factors that predict risk for neuropathy is critical, as these patients may in particular benefit from the lower risk of neuropathy associated with eribulin therapy. In conjunction with this trial, we have included correlative studies to study the proposed pharmacogenomic factors associated with risk of neuropathy. In this way we will potentially be able to identify patients who could preferentially be treated with less neurotoxic microtubule inhibitors.

Study Design

• Study Type: Interventional
• Actual Enrollment: 44 participants
• Allocation: Non-Randomized
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Phase Ib/II Study of Eribulin in Combination With Cyclophosphamide in Patients With Solid Tumor Malignancies
• Actual Study Start Date: Mar 27, 2012
• Actual Primary Completion Date: Dec 31, 2019
• Actual Study Completion Date: Dec 31, 2019

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Phase 1b: 1.1 mg/m2 Eribulin Combination w/ Cyclophosphamide (Solid Tumor Escalation Cohort) Dose escalation cohort will include all patients with solid tumors. Eribulin mesylate 1.1 mg/ m2 on days 1 and 8 followed by cyclophosphamide 600 mg/m2 on day 1 of a 21-day cycle.The highest dose level at which no more than one of six subjects experience DLT defines the MTD	Drug: Eribulin; Given intravenously (IV) Phase II: Eribulin mesylate (mg/m2) + Cyclophosphamide (mg/ m2) for advanced breast cancer participants only; Other Names: Halaven E7389 ER-086526 ; Drug: Cyclophosphamide; Given IV; Other Names: Cytoxan
Experimental: Phase 1b: 1.4 mg/m2 Eribulin Combination w/ Cyclophosphamide (Solid Tumor Escalation Cohort) Dose escalation cohort will include all patients with solid tumors. Eribulin mesylate 1.4 mg/ m2 on days 1 and 8 followed by cyclophosphamide 600 mg/ m2 on day 1 of a 21-day cycle.The highest dose level at which no more than one of six subjects experience DLT defines the MTD	Drug: Eribulin; Given intravenously (IV) Phase II: Eribulin mesylate (mg/m2) + Cyclophosphamide (mg/ m2) for advanced breast cancer participants only; Other Names: Halaven E7389 ER-086526 ; Drug: Cyclophosphamide; Given IV; Other Names: Cytoxan
Experimental: Phase II: Eribulin Combination w/ Cyclophosphamide (Breast Cancer Expansion Cohort) Dose-expansion cohort will enroll patients with advanced breast cancer only after Phase Ib enrollment has been concluded. The MTD of Eribulin mesylate will be administered on days 1 and 8 followed by cyclophosphamide 600 mg/m2 on day 1 of a 21-day cycle.	Drug: Eribulin; Given intravenously (IV) Phase II: Eribulin mesylate (mg/m2) + Cyclophosphamide (mg/ m2) for advanced breast cancer participants only; Other Names: Halaven E7389 ER-086526 ; Drug: Cyclophosphamide; Given IV; Other Names: Cytoxan

Outcome Measures

Primary Outcome Measures

1. Maximum Tolerated Dose (MTD) in Participants With Any Solid Tumor (Phase Ib) [Up to 24 months]

   Standard dose-confirmation design of 3 to 6 participants per cohort (3+3 design) was used to determine the MTD of eribulin in combination with cyclophosphamide for participants with any solid tumor. The highest dose level or MTD is reached when no more than one of six participants experience a Dose Limiting Toxicity (DLTs). A DLT is defined as any treatment-related toxicity in first 28 days of therapy with a grade 3 or 4 non-hematologic toxicity, a grade 4 neutropenia or thrombocytopenia lasting >7 days or febrile neutropenia, or any clinically significant toxicity grade 2 or higher that requires more than 14 days to resolve. The highest dose level at which no more than one of six participants experience DLT defines the MTD.

2. Clinical Benefit Rate for Patients With Advanced Breast Cancer (ABC) (Phase II) [Up to 24 months]

   The clinical benefit rate is defined as the proportion of participants with confirmed complete response (CR), partial response (PR) and stable disease (SD) evaluated using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. Responses are determined by changes in the largest diameter of the tumor lesions and the shortest diameter in the case of malignant lymph nodes. CR is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 millimeter, PR is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters, and SD is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease. Only participants with measurable disease present at baseline, received at least 1 cycle of therapy, and had disease re-evaluated will be considered evaluable.

Secondary Outcome Measures

1. Number of Participants With Treatment-related Toxicities [Up to 24 months]

   Safety of combination of eribulin and cyclophosphamide in participants was assessed by monitoring the frequency of treatment-related toxicities according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 with an attribute of possibly, probably, or definitely related to treatment. Number of participants by toxicity will be reported.

2. Number of Participants With Dose Limiting Toxicity (DLT) for Participants With Any Solid Tumor (Phase 1b) [Up to 24 months]

   For the purposes of Phase Ib dose escalation, DLTs will be defined as any treatment-related toxicity occurring within the first 21 days of combination therapy as grade 3 or 4 clinically evident non-hematologic toxicity; grade 4 neutropenia or thrombocytopenia lasting > 7 days or febrile neutropenia; or any clinically significant toxicity grade 2 or higher that requires more than 14 days to resolve.

3. Overall Response Rate (ORR) for Participants With Advanced Breast Cancer (Phase II) [Up to 24 months]

   The ORR is defined as the proportion of participants displaying a CR or PR per RECIST criteria recorded from the start of the treatment until disease progression/recurrence (taking as reference for progressive disease the smallest measurements recorded since the treatment started). The participant's best response will depend on the achievement of both measurement and confirmation criteria with CR defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 millimeter and PR is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters.

4. Time to Progression for Participants With Advanced Breast Cancer (Phase II) [Up to 24 months]

   Time to progression will be evaluated as time from first treatment to tumor progression in weeks. Disease progression will be measured using Response Evaluation Criteria in Solid Tumors (RECIST) guideline (version 1.1). Changes in the largest diameter (uni-dimensional measurement) of the tumor lesions and the shortest diameter in the case of malignant lymph nodes are used in the RECIST 1.1 criteria.

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years to 80 Years
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

INCLUSION CRITERIA:

1. Phase Ib: Patient must have histologically or cytologically documented solid tumor malignancies.

Phase II: Patients must have histologically or cytologically confirmed locally advanced, unresectable or metastatic carcinoma of the breast.

1. Patient is male or female and ≥18 years of age on the day of signing informed consent.

2. Patient must have performance status of 0-2 on the Eastern Cooperative Oncology Group (ECOG) Performance Scale and life expectancy > 3 months.

3. Patient must have evaluable disease. Measureable disease is not required

4. Patient must have adequate organ function

5. Female patient of childbearing potential must have a negative serum or urine pregnancy test quantitative human chorionic gonadotropin (β-hCG) within 72 hours prior to receiving the first dose of study medication and agree to the use of effective methods of contraception while on study.

6. Any number of prior lines of chemotherapy in the metastatic setting is allowed.

7. Concomitant use of bisphosphonates is allowed.

8. Patients with stable and clinically insignificant CNS disease are allowed. Patients must be off steroids with no new CNS symptoms or findings on radiographic imaging for 1 month.

9. Patients willing and able to complete the questionnaires.

10. Patients willing and able to comply with the study protocol for the duration of the study.

11. Written informed consent prior to any study-specific screening procedures with the understanding that the patient may withdraw consent at any time without prejudice.

EXCLUSION CRITERIA:

1. Patients who have had chemotherapy or radiotherapy within two weeks, 4 weeks for nitrosoureas, mitomycin C, pegylated-doxorubicin and one half-life for bevacizumab, hormone therapy within one week, trastuzumab within 2 weeks or lapatinib within one week of study Day 1.

2. If the patient has residual toxicity from prior treatment, toxicity must be ≤ Grade 1.

3. Patients with non-healing surgical wounds. Patients must be at least two weeks from a major surgical procedure, and surgical wounds must be completely healed.

4. Patients with known active central nervous system (CNS) metastases and/or carcinomatous meningitis. However, patients with CNS metastases who have completed a course of therapy would be eligible for the study provided they are clinically stable for at least 1 month prior to entry as defined as:

5. no evidence of new or enlarging CNS metastasis

6. off steroids that are used to minimize surrounding brain edema. Patients with clinically insignificant brain metastases that do not require treatment are eligible.

7. Patients with known hypersensitivity to the components of study drug or its analogs.

8. Significant cardiovascular impairment:

9. Congestive heart failure, Clinically significant cardiac arrhythmia, history or current evidence of a myocardial infarction during the last 6 months, and/or a current ECG tracing that is abnormal in the opinion of the treating Investigator, or unstable angina

10. QTc prolongation >480 msec (Bazett's Formula) or congenitally long QT syndrome (LQTS)

11. Severe/uncontrolled concurrent illness/infection

12. Patients with other active, current primary malignancies, other than carcinoma in situ of the cervix or non-melanoma skin cancer

13. Patients with > Grade 1 neuropathy at screening

14. Patients with a hypersensitivity to halichondrin B and/or halichondrin B chemical derivative

15. Patient is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the study.

16. Patients with other significant disease or disorders that, in the Investigator's opinion, would exclude the patient from the study

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	University of California, San Francisco	San Francisco	California	United States	94143

Sponsors and Collaborators

• University of California, San Francisco
• Eisai Inc.

Investigators

• Principal Investigator: Hope S Rugo, MD, University of California, San Francisco

Study Documents (Full-Text)

• Study Protocol and Statistical Analysis Plan - May 26, 2017
• Informed Consent Form - Apr 9, 2019

More Information

Publications

None provided.

• Responsible Party: University of California, San Francisco
• ClinicalTrials.gov Identifier: NCT01554371
• Other Study ID Numbers: 11996; NCI-2012-00436
• First Posted: Mar 15, 2012
• Last Update Posted: Feb 3, 2021
• Last Verified: Jan 1, 2021

• Individual Participant Data (IPD) Sharing Statement: No
• Plan to Share IPD: No
• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No
• Keywords provided by University of California, San Francisco: Solid tumor; Metastatic breast cancer; Unresectable or metastatic carcinoma; Neuropathy; Eribulin; Cyclophosphamide
• Additional relevant MeSH terms: Breast Neoplasms; Cyclophosphamide

Study Results

Participant Flow

Arm/Group Title	Phase 1b: 1.1 mg/m2 Eribulin Combination w/ Cyclophosphamide (Solid Tumor Escalation Cohort)	Phase 1b: 1.4 mg/m2 Eribulin Combination w/ Cyclophosphamide (Solid Tumor Escalation Cohort)	Phase II: Eribulin Combination w/ Cyclophosphamide (Breast Cancer Expansion Cohort)
Arm/Group Description	Dose escalation cohort will include all patients with solid tumors. Eribulin mesylate 1.1 mg/ m2 on days 1 and 8 followed by cyclophosphamide 600 mg/ m2 on day 1 of a 21-day cycle.The highest dose level at which no more than one of six subjects experience DLT defines the MTD Eribulin: Given intravenously (IV) Cyclophosphamide: Given IV	Dose escalation cohort will include all patients with solid tumors. Eribulin mesylate 1.4 mg/ m2 on days 1 and 8 followed by cyclophosphamide 600 mg/ m2 on day 1 of a 21-day cycle.The highest dose level at which no more than one of six subjects experience DLT defines the MTD Eribulin: Given intravenously (IV) Cyclophosphamide: Given IV	Dose-expansion cohort will enroll patients with advanced breast cancer only after Phase Ib enrollment has been concluded. The MTD of Eribulin mesylate will be administered on days 1 and 8 followed by cyclophosphamide 600 mg/m2 on day 1 of a 21-day cycle. Eribulin: Given intravenously (IV) Cyclophosphamide: Given IV
Period Title: Overall Study
STARTED	3	3	38
COMPLETED	3	3	38
NOT COMPLETED	0	0	0

Baseline Characteristics

Arm/Group Title	Phase 1b: 1.1 mg/m2 Eribulin Combination w/ Cyclophosphamide (Solid Tumor Escalation Cohort)	Phase 1b: 1.4 mg/m2 Eribulin Combination w/ Cyclophosphamide (Solid Tumor Escalation Cohort)	Phase II: Eribulin Combination w/ Cyclophosphamide (Breast Cancer Expansion Cohort)	Total
Arm/Group Description	Dose escalation cohort will include all patients with solid tumors. Eribulin mesylate 1.1 mg/m2 on days 1 and 8 followed by cyclophosphamide 600 mg/m2 on day 1 of a 21-day cycle. The highest dose level at which no more than one of six subjects experience DLT defines the MTD Eribulin: Given intravenously (IV) Cyclophosphamide: Given IV	Dose escalation cohort will include all patients with solid tumors. Eribulin mesylate 1.4 mg/m2 on days 1 and 8 followed by cyclophosphamide 600 mg/m2 on day 1 of a 21-day cycle. The highest dose level at which no more than one of six subjects experience DLT defines the MTD Eribulin: Given intravenously (IV) Cyclophosphamide: Given IV	Dose-expansion cohort will enroll patients with advanced breast cancer only after Phase Ib enrollment has been concluded. The MTD of Eribulin mesylate will be administered on days 1 and 8 followed by cyclophosphamide 600 mg/m2 on day 1 of a 21-day cycle. Eribulin: Given intravenously (IV) Cyclophosphamide: Given IV	Total of all reporting groups
Overall Participants	3	3	38	44
Age, Customized (Count of Participants)
30-39 years old	0 0%	0 0%	1 2.6%	1 2.3%
40-49 years old	1 33.3%	2 66.7%	12 31.6%	15 34.1%
50-59 years old	1 33.3%	0 0%	10 26.3%	11 25%
60-69 years old	1 33.3%	1 33.3%	11 28.9%	13 29.5%
70-79 years old	0 0%	0 0%	3 7.9%	3 6.8%
80-89 years old	0 0%	0 0%	1 2.6%	1 2.3%
Sex: Female, Male (Count of Participants)
Female	3 100%	3 100%	38 100%	44 100%
Male	0 0%	0 0%	0 0%	0 0%
Ethnicity (NIH/OMB) (Count of Participants)
Hispanic or Latino	1 33.3%	0 0%	1 2.6%	2 4.5%
Not Hispanic or Latino	2 66.7%	3 100%	36 94.7%	41 93.2%
Unknown or Not Reported	0 0%	0 0%	1 2.6%	1 2.3%
Race (NIH/OMB) (Count of Participants)
American Indian or Alaska Native	0 0%	0 0%	0 0%	0 0%
Asian	0 0%	1 33.3%	2 5.3%	3 6.8%
Native Hawaiian or Other Pacific Islander	0 0%	0 0%	0 0%	0 0%
Black or African American	0 0%	0 0%	3 7.9%	3 6.8%
White	3 100%	2 66.7%	29 76.3%	34 77.3%
More than one race	0 0%	0 0%	0 0%	0 0%
Unknown or Not Reported	0 0%	0 0%	4 10.5%	4 9.1%
Region of Enrollment (participants) [Number]
United States	3 100%	3 100%	38 100%	44 100%

Outcome Measures

1. Primary Outcome

Title	Maximum Tolerated Dose (MTD) in Participants With Any Solid Tumor (Phase Ib)
Description	Standard dose-confirmation design of 3 to 6 participants per cohort (3+3 design) was used to determine the MTD of eribulin in combination with cyclophosphamide for participants with any solid tumor. The highest dose level or MTD is reached when no more than one of six participants experience a Dose Limiting Toxicity (DLTs). A DLT is defined as any treatment-related toxicity in first 28 days of therapy with a grade 3 or 4 non-hematologic toxicity, a grade 4 neutropenia or thrombocytopenia lasting >7 days or febrile neutropenia, or any clinically significant toxicity grade 2 or higher that requires more than 14 days to resolve. The highest dose level at which no more than one of six participants experience DLT defines the MTD.
Time Frame	Up to 24 months

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Phase 1b: Eribulin Combination w/ Cyclophosphamide (Solid Tumor Escalation Cohort)
Arm/Group Description	Dose escalation cohort will include all patients with solid tumors. Eribulin mesylate 1.1 mg/ m2 on days 1 and 8 followed by cyclophosphamide 600 mg/ m2 on day 1 of a 21-day cycle.The highest dose level at which no more than one of six subjects experience DLT defines the MTD Eribulin: Given intravenously (IV) Cyclophosphamide: Given IV
Measure Participants	6
Eribulin	1.4
Cyclophosphamide	600

2. Primary Outcome

Title	Clinical Benefit Rate for Patients With Advanced Breast Cancer (ABC) (Phase II)
Description	The clinical benefit rate is defined as the proportion of participants with confirmed complete response (CR), partial response (PR) and stable disease (SD) evaluated using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. Responses are determined by changes in the largest diameter of the tumor lesions and the shortest diameter in the case of malignant lymph nodes. CR is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 millimeter, PR is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters, and SD is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease. Only participants with measurable disease present at baseline, received at least 1 cycle of therapy, and had disease re-evaluated will be considered evaluable.
Time Frame	Up to 24 months

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Phase II: Eribulin Combination w/ Cyclophosphamide (Breast Cancer Expansion Cohort)
Arm/Group Description	Dose-expansion cohort will enroll patients with advanced breast cancer only after Phase Ib enrollment has been concluded. The MTD of Eribulin mesylate will be administered on days 1 and 8 followed by cyclophosphamide 600 mg/m2 on day 1 of a 21-day cycle. Eribulin: Given intravenously (IV) Cyclophosphamide: Given IV
Measure Participants	38
Number [proportion of particpants]	.135

3. Secondary Outcome

Title	Number of Participants With Treatment-related Toxicities
Description	Safety of combination of eribulin and cyclophosphamide in participants was assessed by monitoring the frequency of treatment-related toxicities according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 with an attribute of possibly, probably, or definitely related to treatment. Number of participants by toxicity will be reported.
Time Frame	Up to 24 months

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Phase 1b: 1.1 mg/m2 Eribulin Combination w/ Cyclophosphamide (Solid Tumor Escalation Cohort)	Phase 1b: 1.4 mg/m2 Eribulin Combination w/ Cyclophosphamide (Solid Tumor Escalation Cohort)	Phase II: Eribulin Combination w/ Cyclophosphamide (Breast Cancer Expansion Cohort)
Arm/Group Description	Dose escalation cohort will include all patients with solid tumors. Eribulin mesylate 1.1 mg/ m2 on days 1 and 8 followed by cyclophosphamide 600 mg/m2 on day 1 of a 21-day cycle.The highest dose level at which no more than one of six subjects experience DLT defines the MTD Eribulin: Given intravenously (IV) Cyclophosphamide: Given IV	Dose escalation cohort will include all patients with solid tumors. Eribulin mesylate 1.4 mg/ m2 on days 1 and 8 followed by cyclophosphamide 600 mg/m2 on day 1 of a 21-day cycle.The highest dose level at which no more than one of six subjects experience DLT defines the MTD Eribulin: Given intravenously (IV) Cyclophosphamide: Given IV	Dose-expansion cohort will enroll patients with advanced breast cancer only after Phase Ib enrollment has been concluded. The MTD of Eribulin mesylate will be administered on days 1 and 8 followed by cyclophosphamide 600 mg/m2 on day 1 of a 21-day cycle. Eribulin: Given intravenously (IV) Cyclophosphamide: Given IV
Measure Participants	3	3	38
Nausea	3 100%	3 100%	19 50%
Constipation	3 100%	1 33.3%	0 0%
Fatigue	1 33.3%	3 100%	26 68.4%
Peripheral sensory neuropathy	2 66.7%	1 33.3%	15 39.5%
Anorexia	1 33.3%	2 66.7%	13 34.2%
White blood cell decreased	1 33.3%	2 66.7%	18 47.4%
Mucositis oral	1 33.3%	1 33.3%	3 7.9%
Platelet count decreased	0 0%	2 66.7%	5 13.2%
Alopecia	1 33.3%	1 33.3%	9 23.7%
Arthralgia	1 33.3%	1 33.3%	2 5.3%
Hemoglobin increased	0 0%	1 33.3%	0 0%
Headache	1 33.3%	0 0%	4 10.5%
Chills	0 0%	1 33.3%	3 7.9%
Alanine aminotransferase increased	1 33.3%	0 0%	0 0%
Rash maculo-papular	0 0%	1 33.3%	3 7.9%
Epistaxis	1 33.3%	0 0%	0 0%
Hypomagnesemia	1 33.3%	0 0%	3 7.9%
Edema limbs	1 33.3%	0 0%	3 7.9%
Vomiting	1 33.3%	0 0%	10 26.3%
Abdominal pain	0 0%	1 33.3%	3 7.9%
Anemia	0 0%	0 0%	13 34.2%
Investigations - Other	0 0%	1 33.3%	5 13.2%
Dysgeusia	1 33.3%	0 0%	0 0%
Alkaline phosphatase increased	1 33.3%	0 0%	2 5.3%
Hoarseness	1 33.3%	0 0%	2 5.3%
Fever	0 0%	1 33.3%	8 21.1%
Neutrophil count decreased	0 0%	0 0%	23 60.5%
Diarrhea	0 0%	0 0%	10 26.3%
Hypokalemia	0 0%	0 0%	8 21.1%
Weight loss	0 0%	0 0%	8 21.1%
Gastrointestinal disorders - Other	0 0%	0 0%	6 15.8%
Nasal congestion	0 0%	0 0%	5 13.2%
Cough	0 0%	0 0%	5 13.2%
Upper respiratory infection	0 0%	0 0%	5 13.2%
Sinusitis	0 0%	0 0%	3 7.9%
Febrile neutropenia	0 0%	0 0%	3 7.9%
Bone pain	0 0%	0 0%	3 7.9%
Blurred vision	0 0%	0 0%	3 7.9%
Peripheral motor neuropathy	0 0%	0 0%	3 7.9%
Dyspnea	0 0%	0 0%	3 7.9%
Gastroesophageal reflux disease	0 0%	0 0%	3 7.9%
Lymphocyte count decreased	0 0%	0 0%	2 5.3%
Dizziness	0 0%	0 0%	2 5.3%
Hypoalbuminemia	0 0%	0 0%	2 5.3%
Hot flashes	0 0%	0 0%	2 5.3%
Aspartate aminotransferase increased	0 0%	0 0%	2 5.3%
Memory impairment	0 0%	0 0%	2 5.3%
Postnasal Drip	0 0%	0 0%	2 5.3%
Insomnia	0 0%	0 0%	2 5.3%
Pain	0 0%	0 0%	2 5.3%
Non-cardiac chest pain	0 0%	0 0%	2 5.3%
Hypoxia	0 0%	0 0%	1 2.6%
Portal vein thrombosis	0 0%	0 0%	1 2.6%
Sepsis	0 0%	0 0%	1 2.6%
Confusion	0 0%	0 0%	1 2.6%
Hypophosphatemia	0 0%	0 0%	1 2.6%
Pain in extremity	0 0%	0 0%	2 5.3%
Hypercalcemia	0 0%	0 0%	1 2.6%
Dysphagia	0 0%	0 0%	1 2.6%
Hyponatremia	0 0%	0 0%	1 2.6%
Myalgia	0 0%	0 0%	1 2.6%

4. Secondary Outcome

Title	Number of Participants With Dose Limiting Toxicity (DLT) for Participants With Any Solid Tumor (Phase 1b)
Description	For the purposes of Phase Ib dose escalation, DLTs will be defined as any treatment-related toxicity occurring within the first 21 days of combination therapy as grade 3 or 4 clinically evident non-hematologic toxicity; grade 4 neutropenia or thrombocytopenia lasting > 7 days or febrile neutropenia; or any clinically significant toxicity grade 2 or higher that requires more than 14 days to resolve.
Time Frame	Up to 24 months

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Phase 1b: 1.1 mg/m2 Eribulin Combination w/ Cyclophosphamide (Solid Tumor Escalation Cohort)	Phase 1b: 1.4 mg/m2 Eribulin Combination w/ Cyclophosphamide (Solid
Arm/Group Description	Dose escalation cohort will include all patients with solid tumors. Eribulin mesylate 1.1 mg/ m2 on days 1 and 8 followed by cyclophosphamide 600 mg/m2 on day 1 of a 21-day cycle.The highest dose level at which no more than one of six subjects experience DLT defines the MTD Eribulin: Given intravenously (IV) Cyclophosphamide: Given IV	Dose escalation cohort will include all patients with solid tumors. Eribulin mesylate 1.4 mg/ m2 on days 1 and 8 followed by cyclophosphamide 600 mg/m2 on day 1 of a 21-day cycle.The highest dose level at which no more than one of six subjects experience DLT defines the MTD Eribulin: Given intravenously (IV) Cyclophosphamide: Given IV
Measure Participants	3	3
Count of Participants [Participants]	0 0%	0 0%

5. Secondary Outcome

Title	Overall Response Rate (ORR) for Participants With Advanced Breast Cancer (Phase II)
Description	The ORR is defined as the proportion of participants displaying a CR or PR per RECIST criteria recorded from the start of the treatment until disease progression/recurrence (taking as reference for progressive disease the smallest measurements recorded since the treatment started). The participant's best response will depend on the achievement of both measurement and confirmation criteria with CR defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 millimeter and PR is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters.
Time Frame	Up to 24 months

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Phase II: Eribulin Combination w/ Cyclophosphamide (Breast Cancer Expansion Cohort)
Arm/Group Description	Dose-expansion cohort will enroll patients with advanced breast cancer only after Phase Ib enrollment has been concluded. The MTD of Eribulin mesylate will be administered on days 1 and 8 followed by cyclophosphamide 600 mg/m2 on day 1 of a 21-day cycle. Eribulin: Given intravenously (IV) Cyclophosphamide: Given IV
Measure Participants	38
Number [proportion of participants]	.131 4.4%

6. Secondary Outcome

Title	Time to Progression for Participants With Advanced Breast Cancer (Phase II)
Description	Time to progression will be evaluated as time from first treatment to tumor progression in weeks. Disease progression will be measured using Response Evaluation Criteria in Solid Tumors (RECIST) guideline (version 1.1). Changes in the largest diameter (uni-dimensional measurement) of the tumor lesions and the shortest diameter in the case of malignant lymph nodes are used in the RECIST 1.1 criteria.
Time Frame	Up to 24 months

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Phase II: Eribulin Combination w/ Cyclophosphamide (Breast Cancer Expansion Cohort)
Arm/Group Description	Dose-expansion cohort will enroll patients with advanced breast cancer only after Phase Ib enrollment has been concluded. The MTD of Eribulin mesylate will be administered on days 1 and 8 followed by cyclophosphamide 600 mg/m2 on day 1 of a 21-day cycle. Eribulin: Given intravenously (IV) Cyclophosphamide: Given IV
Measure Participants	38
Median (95% Confidence Interval) [weeks]	16.4

Adverse Events

Time Frame	Up to 5 years
Arm/Group Title	Phase 1b: 1.1 mg/m2 Eribulin Combination w/ Cyclophosphamide (Solid Tumor Escalation Cohort)		Phase 1b: 1.4 mg/m2 Eribulin Combination w/ Cyclophosphamide (Solid Tumor Escalation Cohort)		Phase II: Eribulin Combination w/ Cyclophosphamide (Breast Cancer Expansion Cohort)
Arm/Group Description	Dose escalation cohort will include all patients with solid tumors. Eribulin mesylate 1.1 mg/ m2 on days 1 and 8 followed by cyclophosphamide 600 mg/m2 on day 1 of a 21-day cycle.The highest dose level at which no more than one of six subjects experience DLT defines the MTD Eribulin: Given intravenously (IV) Cyclophosphamide: Given IV		Dose escalation cohort will include all patients with solid tumors. Eribulin mesylate 1.4 mg/ m2 on days 1 and 8 followed by cyclophosphamide 600 mg/m2 on day 1 of a 21-day cycle.The highest dose level at which no more than one of six subjects experience DLT defines the MTD Eribulin: Given intravenously (IV) Cyclophosphamide: Given IV		Dose-expansion cohort will enroll patients with advanced breast cancer only after Phase Ib enrollment has been concluded. The MTD of Eribulin mesylate will be administered on days 1 and 8 followed by cyclophosphamide 600 mg/m2 on day 1 of a 21-day cycle. Eribulin: Given intravenously (IV) Cyclophosphamide: Given IV
All Cause Mortality
	Phase 1b: 1.1 mg/m2 Eribulin Combination w/ Cyclophosphamide (Solid Tumor Escalation Cohort)		Phase 1b: 1.4 mg/m2 Eribulin Combination w/ Cyclophosphamide (Solid Tumor Escalation Cohort)		Phase II: Eribulin Combination w/ Cyclophosphamide (Breast Cancer Expansion Cohort)
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	1/3 (33.3%)		3/3 (100%)		32/38 (84.2%)
Serious Adverse Events
	Phase 1b: 1.1 mg/m2 Eribulin Combination w/ Cyclophosphamide (Solid Tumor Escalation Cohort)		Phase 1b: 1.4 mg/m2 Eribulin Combination w/ Cyclophosphamide (Solid Tumor Escalation Cohort)		Phase II: Eribulin Combination w/ Cyclophosphamide (Breast Cancer Expansion Cohort)
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	0/3 (0%)		1/3 (33.3%)		5/38 (13.2%)
Blood and lymphatic system disorders
Anemia	0/3 (0%)	0	0/3 (0%)	0	1/38 (2.6%)	1
Febrile neutropenia	0/3 (0%)	0	0/3 (0%)	0	1/38 (2.6%)	1
General disorders
Fever	0/3 (0%)	0	1/3 (33.3%)	1	1/38 (2.6%)	1
Investigations
Low Hematocrit	0/3 (0%)	0	0/3 (0%)	0	1/38 (2.6%)	1
Neutrophil count decreased	0/3 (0%)	0	0/3 (0%)	0	1/38 (2.6%)	1
Other (Not Including Serious) Adverse Events
	Phase 1b: 1.1 mg/m2 Eribulin Combination w/ Cyclophosphamide (Solid Tumor Escalation Cohort)		Phase 1b: 1.4 mg/m2 Eribulin Combination w/ Cyclophosphamide (Solid Tumor Escalation Cohort)		Phase II: Eribulin Combination w/ Cyclophosphamide (Breast Cancer Expansion Cohort)
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	3/3 (100%)		3/3 (100%)		38/38 (100%)
Blood and lymphatic system disorders
Anemia	0/3 (0%)	0	1/3 (33.3%)	1	0/38 (0%)	0
Febrile neutropenia	0/3 (0%)	0	0/3 (0%)	0	3/38 (7.9%)	3
Cardiac disorders
Sinus tachycardia	0/3 (0%)	0	0/3 (0%)	0	3/38 (7.9%)	3
Ear and labyrinth disorders
Ear pain	0/3 (0%)	0	0/3 (0%)	0	2/38 (5.3%)	2
Tinnitus	0/3 (0%)	0	0/3 (0%)	0	2/38 (5.3%)	2
Vestibular disorder	0/3 (0%)	0	0/3 (0%)	0	2/38 (5.3%)	2
Eye disorders
Watering eyes	0/3 (0%)	0	0/3 (0%)	0	6/38 (15.8%)	6
Blurred vision	0/3 (0%)	0	1/3 (33.3%)	1	0/38 (0%)	0
Gastrointestinal disorders
Nausea	3/3 (100%)	5	3/3 (100%)	6	0/38 (0%)	0
Constipation	3/3 (100%)	3	1/3 (33.3%)	1	0/38 (0%)	0
Vomiting	1/3 (33.3%)	1	0/3 (0%)	0	0/38 (0%)	0
Diarrhea	1/3 (33.3%)	1	0/3 (0%)	0	0/38 (0%)	0
Abdominal pain	0/3 (0%)	0	1/3 (33.3%)	1	0/38 (0%)	0
Gastrointestinal disorders - Other	1/3 (33.3%)	1	0/3 (0%)	0	0/38 (0%)	0
Abdominal distension	0/3 (0%)	0	0/3 (0%)	0	5/38 (13.2%)	5
Mucositis oral	1/3 (33.3%)	1	1/3 (33.3%)	1	0/38 (0%)	0
Gastroesophageal reflux disease	0/3 (0%)	0	0/3 (0%)	0	4/38 (10.5%)	5
Bloating	0/3 (0%)	0	0/3 (0%)	0	3/38 (7.9%)	3
Hemorrhoidal hemorrhage	0/3 (0%)	0	1/3 (33.3%)	1	0/38 (0%)	0
Oral pain	0/3 (0%)	0	1/3 (33.3%)	1	0/38 (0%)	0
Dysphagia	0/3 (0%)	0	0/3 (0%)	0	2/38 (5.3%)	2
Fecal incontinence	0/3 (0%)	0	0/3 (0%)	0	2/38 (5.3%)	2
Toothache	0/3 (0%)	0	0/3 (0%)	0	2/38 (5.3%)	2
General disorders
Fatigue	1/3 (33.3%)	1	1/3 (33.3%)	4	0/38 (0%)	0
Edema Limbs	1/3 (33.3%)	1	0/3 (0%)	0	0/38 (0%)	0
Fever	0/3 (0%)	0	1/3 (33.3%)	1	0/38 (0%)	0
Non-cardiac chest pain	0/3 (0%)	0	0/3 (0%)	0	7/38 (18.4%)	9
Pain	0/3 (0%)	0	0/3 (0%)	0	7/38 (18.4%)	12
Chills	0/3 (0%)	0	1/3 (33.3%)	1	0/38 (0%)	0
Flu like symptoms	0/3 (0%)	0	1/3 (33.3%)	1	0/38 (0%)	0
Infections and infestations
Upper respiratory infection	0/3 (0%)	0	0/3 (0%)	0	11/38 (28.9%)	12
Sinusitis	0/3 (0%)	0	0/3 (0%)	0	3/38 (7.9%)	7
Urinary tract infection	0/3 (0%)	0	0/3 (0%)	0	2/38 (5.3%)	2
Injury, poisoning and procedural complications
Fall	0/3 (0%)	0	0/3 (0%)	0	5/38 (13.2%)	15
Investigations
Neutrophil count decreased	0/3 (0%)	0	2/3 (66.7%)	7	0/38 (0%)	0
White blood cell decreased	1/3 (33.3%)	1	2/3 (66.7%)	6	0/38 (0%)	0
Investigations - Other	1/3 (33.3%)	1	1/3 (33.3%)	1	0/38 (0%)	0
Weight Loss	0/3 (0%)	0	0/3 (0%)	0	10/38 (26.3%)	12
Platelet count decreased	0/3 (0%)	0	2/3 (66.7%)	2	0/38 (0%)	0
Aspartate aminotransferase increased	0/3 (0%)	0	0/3 (0%)	0	5/38 (13.2%)	5
Alkaline phosphatase increased	1/3 (33.3%)	1	0/3 (0%)	0	0/38 (0%)	0
Alanine aminotransferase increased	1/3 (33.3%)	1	0/3 (0%)	0	0/38 (0%)	0
Lymphocyte count decreased	0/3 (0%)	0	0/3 (0%)	0	2/38 (5.3%)	6
Hemoglobin increased	0/3 (0%)	0	1/3 (33.3%)	1	0/38 (0%)	0
Metabolism and nutrition disorders
Anorexia	1/3 (33.3%)	1	2/3 (66.7%)	3	0/38 (0%)	0
Hypokalemia	0/3 (0%)	0	0/3 (0%)	0	9/38 (23.7%)	20
Hypoalbuminemia	0/3 (0%)	0	1/3 (33.3%)	1	0/38 (0%)	0
Hypomagnesemia	1/3 (33.3%)	1	0/3 (0%)	0	0/38 (0%)	0
Hyperglycemia	1/3 (33.3%)	3	0/3 (0%)	0	0/38 (0%)	0
Hypercalcemia	0/3 (0%)	0	0/3 (0%)	0	2/38 (5.3%)	2
Hypocalcemia	0/3 (0%)	0	0/3 (0%)	0	2/38 (5.3%)	3
Hyponatremia	0/3 (0%)	0	0/3 (0%)	0	2/38 (5.3%)	2
Musculoskeletal and connective tissue disorders
Arthralgia	2/3 (66.7%)	5	1/3 (33.3%)	1	0/38 (0%)	0
Back pain	0/3 (0%)	0	0/3 (0%)	0	12/38 (31.6%)	13
Pain in extremity	0/3 (0%)	0	0/3 (0%)	0	11/38 (28.9%)	14
Bone pain	0/3 (0%)	0	0/3 (0%)	0	8/38 (21.1%)	10
Muscle weakness lower limb	0/3 (0%)	0	0/3 (0%)	0	3/38 (7.9%)	4
Myalgia	1/3 (33.3%)	1	0/3 (0%)	0	0/38 (0%)	0
Neck pain	0/3 (0%)	0	0/3 (0%)	0	3/38 (7.9%)	4
Muscle weakness upper limb	0/3 (0%)	0	0/3 (0%)	0	2/38 (5.3%)	2
Nervous system disorders
Peripheral sensory neuropathy	2/3 (66.7%)	3	1/3 (33.3%)	2	0/38 (0%)	0
Headache	1/3 (33.3%)	1	1/3 (33.3%)	1	0/38 (0%)	0
Dizziness	0/3 (0%)	0	0/3 (0%)	0	8/38 (21.1%)	10
Peripheral motor neuropathy	0/3 (0%)	0	0/3 (0%)	0	4/38 (10.5%)	7
Memory impairment	0/3 (0%)	0	0/3 (0%)	0	2/38 (5.3%)	2
Presyncope	0/3 (0%)	0	0/3 (0%)	0	2/38 (5.3%)	2
Dysgeusia	1/3 (33.3%)	1	0/3 (0%)	0	0/38 (0%)	0
Psychiatric disorders
Insomnia	0/3 (0%)	0	0/3 (0%)	0	9/38 (23.7%)	9
Depression	0/3 (0%)	0	0/3 (0%)	0	6/38 (15.8%)	6
Anxiety	0/3 (0%)	0	0/3 (0%)	0	4/38 (10.5%)	4
Confusion	0/3 (0%)	0	0/3 (0%)	0	2/38 (5.3%)	2
Renal and urinary disorders
Urinary frequency	0/3 (0%)	0	0/3 (0%)	0	4/38 (10.5%)	4
Urinary incontinence	0/3 (0%)	0	0/3 (0%)	0	3/38 (7.9%)	3
Urinary urgency	0/3 (0%)	0	0/3 (0%)	0	3/38 (7.9%)	3
Urinary Tract Pain	0/3 (0%)	0	1/3 (33.3%)	1	0/38 (0%)	0
Reproductive system and breast disorders
Pelvic pain	0/3 (0%)	0	0/3 (0%)	0	2/38 (5.3%)	2
Vaginal discharge	0/3 (0%)	0	0/3 (0%)	0	2/38 (5.3%)	2
Respiratory, thoracic and mediastinal disorders
Dyspnea	0/3 (0%)	0	0/3 (0%)	0	18/38 (47.4%)	27
Cough	0/3 (0%)	0	0/3 (0%)	0	9/38 (23.7%)	10
Nasal congestion	0/3 (0%)	0	0/3 (0%)	0	9/38 (23.7%)	10
Productive cough	0/3 (0%)	0	0/3 (0%)	0	6/38 (15.8%)	7
Allergic rhinitis	0/3 (0%)	0	0/3 (0%)	0	4/38 (10.5%)	4
Hoarseness	1/3 (33.3%)	1	0/3 (0%)	0	0/38 (0%)	0
Postnasal drip	0/3 (0%)	0	0/3 (0%)	0	3/38 (7.9%)	3
Sore throat	0/3 (0%)	0	0/3 (0%)	0	3/38 (7.9%)	3
Epistaxis	1/3 (33.3%)	1	0/3 (0%)	0	0/38 (0%)	0
Skin and subcutaneous tissue disorders
Alopecia	1/3 (33.3%)	1	2/3 (66.7%)	3	0/38 (0%)	0
Rash maculo-papular	0/3 (0%)	0	2/3 (66.7%)	2	0/38 (0%)	0
Skin hyperpigmentation	0/3 (0%)	0	0/3 (0%)	0	2/38 (5.3%)	2
Vascular disorders
Hot flashes	0/3 (0%)	0	0/3 (0%)	0	3/38 (7.9%)	5
Lymphedema	0/3 (0%)	0	0/3 (0%)	0	2/38 (5.3%)	3
Thromboembolic event	0/3 (0%)	0	0/3 (0%)	0	2/38 (5.3%)	2

Limitations/Caveats

[Not Specified]

More Information

Certain Agreements

All Principal Investigators ARE employed by the organization sponsoring the study.

There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.